ClinicalTrials.gg
CompletedNCT00984659Updated Aug 29, 2018Results posted

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

A Phase 4 interventional study of Fluticasone propionate/salmeterol combination product and Salmeterol in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 39 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-08-29.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Pulmonary Disease, Chronic Obstructive.

Enrollment
12th of 43
366 · median 107
Started
2009
with 5 others
Phase 4
22 of 43
none open now
Registered
26th of 43
by date
Lead sponsor
16 of 43
GlaxoSmithKline

Among the 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive, this one is the 12th largest by enrollment, is one of 6 that started in 2009, is one of 22 in phase 4, and was the 26th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About Salmeterol Xinafoate

Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies testing Salmeterol Xinafoate in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The purpose of this study is to evaluate a new questionnaire to capture the patient experience of COPD. The information collected will be used to validate the Shortness of Breath with Daily Activities Questionnaire.

Read the detailed description

Dyspnea, referred to by patients as "shortness of breath" or "breathlessness," is frequently associated with decreases in functional status, quality of life, and disabilities. Currently available questionnaires do not specifically address the shortness of breath component of COPD. The development of a patient reported outcome questionnaire that will specifically assess Shortness of Breath with Daily Activities (SOBDA) in patients with COPD is needed.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Pulmonary Disease, Chronic Obstructive
  • Dyspnea
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 40 years of age
  • Established clinical history of by ATS/ERS definition
  • Former or current smoker > 10 pack years
  • Evidence of dyspnea

Exclusion criteria

Exclusion Criteria:

  • Has a respiratory disorder other than
  • Cancer not in complete clinical remission
  • cardiovascular, neurological, psychiatric, renal, gastro-intestinal, immunological, endocrine, or hematological abnormalities that are uncontrolled
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    FSC

    Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day

    Drug: Fluticasone propionate/salmeterol combination product

  • Experimental
    SAL

    Salmeterol 50mcg DISKUS twice a day

    Drug: Salmeterol

  • Placebo comparator
    Placebo

    Placebo DISKUS twice a day

    Drug: Placebo

Interventions

  • DrugFluticasone propionate/salmeterol combination product

    Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks

  • Salmeterol 50mcg DISKUS twice a day for 8 weeks

  • DrugPlacebo

    Placebo DISKUS twice a day for 8 weeks

06

What researchers measure

Primary outcomes

  1. Internal Consistency (IC) of the Shortness of Breath With Daily Activities (SOBDA) Questionnaire in Participants With Chronic Obstructive Pulmonary Disease (COPD) Assessed as Cronbach's Alpha Value

    Cronbach's alpha (CA) is a measure of the IC of the 13-item SOBDA questionnaire (completed via electronic diary by a sample of participants). It is the ratio of the variance (var.) of the sum of the individual scores and the var. of the total score. The var. of the sum of a group of independent variables is the sum of their var.; thus, if the variables are positively correlated, the var. of the sum will be increased. If the items making up the score are identical and so perfectly correlated, CA=1. If the items are independent, CA=0. Higher scores indicate a more reliable (precise) instrument.

    Time frame: Day 1 of the 2-week Run-in Period

  2. Test-retest Reliability (T-RR) of SOBDA Scores Measured as the Difference in the SOBDA Weekly Score Between Week 1 and Week 2 of the 2-week Run-in Period

    T-RR=stability during repeat measures over time in a stable population. SOBDA score was determined by the 13-item (it.) scoring algorithm, assigning a weekly mean score of 1-4 (higher scores=more severe breathlessness with daily activities) based on the mean of 7 days of data (or \>=4 days). Daily total score is computed from the mean of the participant's (par.) scores on the 13 it. (\>=7 it. must have non-missing responses). Only scores of stable par. (indicating no change \[score=3\] on the par.-completed Patient Global Assessment of Change \[PGAC\]; 1 \[ much worse\] to 5 \[much better\]) were used.

    Time frame: Week 1 and Week 2 of the 2-week Run-in Period

  3. Convergent Validity for the SOBDA Questionnaire Measured as Correlations of the Baseline SOBDA Score With Participant-completed Modified Medical Research Council (mMRC) and Physician-completed mMRC Scores at Visit 2

    Convergent validity is defined as the ability of the SOBDA questionnaire to measure required information and was assessed by examining the relationship between the SOBDA score and the participant/physician-completed mMRC Dyspnea Scale assessments. The physician/participant rated the degree of the participant's dyspnea (trouble breathing) on the 5-point mMRC scale (0, none; 4, very severe). Spearman's rank correlation coefficient assesses if the relationship between two variables is monotone. A correlation of +1 or -1 will occur if one variable is a perfect monotone of the other.

    Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)

  4. Convergent Validity for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Clinician Global Assessment of Dyspnea Severity (CGI-S) Score at Visit 2

    Convergent validity is defined as the ability of the SOBDA questionnaire to measure the required information and was assessed by examining the relationship between the SOBDA score with the CGI-S score. Spearman's rank correlation coefficient assesses if the relationship between two variables is monotone. A correlation of +1 or -1 will occur if one variable is a perfect monotone of the other. Clinicians were asked to assess the severity of the participant's dyspnea on the CGI-S scale. This was evaluated on a 1-4 Likert scale: 1 (mild) to 4 (very severe).

    Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)

  5. Convergent Validity (CV) for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) Dyspnea Domain Score at Visit 2

    Convergent validity is defined as the ability of the SOBDA questionnaire to measure required information and was assessed by examining the relationship between the SOBDA score and the CRQ-SAS dyspnea domain score. Pearson's correlation coefficient is a measure of the linear dependence between 2 variables. A correlation of +1 or -1 will occur if the data from the 2 variables lie exactly on a line. The CRQ is a 20-item instrument measuring 4 domains (each measured on a scale of 1 \[maximum impairment\] to 7 \[no impairment\]) of functioning: mastery, fatigue, emotional function, and dyspnea.

    Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)

  6. Known Group Validity for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of the Physician-completed (PyC) mMRC Score at Visit 2

    SOBDA known group validity refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the PyC mMRC. The physician rated the degree of the participant's dyspnea on the 5-point mMRC scale: 0 (none) to 4 (very severe). Known group validity was confirmed if the SOBDA score increased with increasing values of PyC mMRC, both indicating increased levels of breathlessness.

    Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)

  7. Known Group Validity for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of the Participant-completed (ParC) mMRC Score at Visit 2

    SOBDA known group validity refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the ParC mMRC. The participant rated the degree of his/her dyspnea on the 5-point mMRC scale: 0 (none) to 4 (very severe). Known group validity was confirmed if the SOBDA score increased with increasing values of ParC mMRC, both indicating increased levels of breathlessness.

    Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)

  8. Known Group Validity (KGV) for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of CGI-S Scores at Visit 2

    SOBDA KGV refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the CGI-S score. Clinicians were asked to assess the severity of the participant's dyspnea on the CGI-S scale. This was evaluated on a 1-4 Likert scale: 1 (mild) to 4 (very severe). KGV was confirmed if the SOBDA score increased with increasing values of CGI-S, both indicating increased levels of breathlessness.

    Time frame: Baseline (last week of the 2-week Run-in Period) and pre-treatement on Visit 2 (Day 1 of the 6-week Treatment Period)

  9. Participants (Par.) Classified as Responders/Non-responders According to the Patient Global Assessment of Change (PGAC) Response at Days 8, 15, 22, 29, 36, and 43 and at Visit 3/Premature Discontinuation (PD) (the End of the 6-week Treatment Period or PD)

    The PGAC is par. completed on a 1-5 scale: 1, much worse; 2, worse; 3, no change; 4, better; 5, much better. Responders were defined as par. with a rating of "better" or "much better" (score of 4 or 5) on the PGAC at the relevant week; non-responders were defined as par. with a response of "much worse," "worse," or "no change" on the PGAC. As pre-specified in the study protocol, results are presented independent of treatment allocation . The study objectives were to assess the measurement properties and validity of the SOBDA questionnaire independent of specific treatment effect.

    Time frame: Days 8, 15, 22, 29, 36, and 43 and Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)

  10. Change From the Previous Week to the Current Week's SOBDA Score by Participant-completed PGAC Response at Days 8, 15, 22, 29, 36, and 43 and at Visit 3/PD (End of the 6-week Treatment Period or PD)

    Responsiveness reflects the ability of the SOBDA questionnaire to detect change under conditions of known change. Responders (Rs)=participants (par.) with a rating of "better"/"much better" (score of 4/5) on the PGAC (range; 1 \[much worse\] to 5 \[much better\]) at the relevant week; NRs=par. with a response of "much worse," "worse," or "no change" (score of 3). Mean difference between Rs and NRs in the change from the previous week to the current week's SOBDA score was calculated. For Visit 3/PD, the change from Baseline to the last treatment week's SOBDA score for Rs and NRs was calculated.

    Time frame: Baseline; Days 8, 15, 22, 29, 36, and 43 and Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)

  11. Number of Participants Classified as Responders and Non-responders by Clinician Global Impression of Change Question (CGI-C) Response at Visit 3/PD

    Clinicians were asked to provide their clinical impression regarding change in the participant's shortness of breath by CGI-C. This was evaluated on a 1-5 Likert scale: 1 (much worse) to 5 (much better), with 3 being no change. A CGI-C responder was defined as a participant who had a response of "better" (4) or "much better" (5), and a non-responder was defined as a participant who had a response of "much worse" (1), "worse" (2), or "no change" (3).

    Time frame: Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)

  12. Number of Participants Classified as Responders and Non-responders by CRQ-SAS Dyspnea Domain Response at Visit 3/PD

    A CRQ-SAS dyspnea domain responder was defined as a participant who had a score increase of 0.5 units or more for the dyspnea domain of the CRQ-SAS between Visit 2 and Visit 3/Premature Discontinuation. A non-responder was defined as a participant who had a decrease in the score, or an increase of less than 0.5 units.

    Time frame: Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)

  13. Number of Participants Classified as Responders and Non-responders by Physician-completed and Participant-completed mMRC Response at Visit 3/PD

    A Physician-completed and Participant-completed mMRC responder was defined as a participant who had a score decrease of one unit or more between Visit 2 and Visit 3/Premature Discontinuation. A non-responder was defined as a participant who had the same score or an increase in score.

    Time frame: Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)

  14. Change From Baseline to Last Treatment Week in the SOBDA Score by CGI-C Responses at Visit 3/PD

    The responsiveness of the SOBDA questionnaire was assessed by comparing score changes between responders and non-responders. The CGI-C is clinician completed on a 1 to 5 scale: 1, much worse; 2, worse; 3, no change; 4, better; 5, much better. Changes in mean SOBDA scores during the last week of treatment in responders and non-responders using definitions based on the CGI-C conducted at Visit 3/Premature Discontinuation were assessed.

    Time frame: Baseline (2-week Run-in Period) and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)

  15. Change From Baseline to Last Treatment Week in the SOBDA Score by CRQ-SAS Dyspnea Domain (DD) Responses at Visit 3/PD

    The responsiveness of the SOBDA questionnaire was assessed by comparing score changes of responders (Rs) versus non-responders (NRs). The CRQ-SAS DD includes 5 questions (q.) scored 1 (maximum impairment) to 7 (no impairment). Individual q. were equally weighted, and domain scores (DSs) (range=1-7) were calculated as the mean across the non-missing items within each domain (DSs were calculated although an individual item score was missing). Changes in mean SOBDA scores during the last treatment week in Rs and NRs using definitions based on the CRQ-SAS DD conducted at Visit 3/PD were assessed.

    Time frame: Baseline (2-week Run-in Period) and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)

  16. Change From Baseline to Last Treatment Week in the SOBDA Score by Physician-completed mMRC and Participant-completed mMRC Responses at Visit 3/PD

    The responsiveness of the SOBDA questionnaire was assessed by comparing score changes between responders and non-responders. The mMRC ranges from 0 (no breathlessness except with strenous exercise) to 4 (too breathless to leave the house; breathless when dressing/undressing) and is completed by the clinician or the participant as indicated. Changes in mean SOBDA scores during the last week of treatment in responders and non-responders using definitions based on the Physician-completed (Ph-C) and Participant-completed (Pa-C) mMRC conducted at Visit 3/Premature Discontinuation were assessed.

    Time frame: Baseline (2-week Run-in Period) and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)

  17. SOBDA Threshold for Response Assessed as Mean Change From the Previous Week's SOBDA Score Based on a Participant-completed PGAC Score Rated of "Better"

    Changes from Baseline in the SOBDA score for responders (Rs) and non-responders (NRs) (using the PGAC assessment; 1 \[much worse\] to 5 \[much better\]), together with the cumulative proportions of Rs and NRs, was used to establish the threshold for defining SOBDA questionnaire Rs. The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on PGAC scores pre-specified as "better" or demonstrating meaningful improvement.

    Time frame: Baseline (last week of the 2-week Run-in Period) and Weeks 1, 2, 3, 4, 5, and 6 (6-week Treatment Period)

  18. SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CGI-C Response Rated as "Better"

    The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on CGI-C scores pre-specified as "better" or demonstrating meaningful improvement. The CGI-C is clinician completed on a 1 to 5 scale: 1, much worse, 2, worse; 3, no change; 4, better; 5, much better.

    Time frame: Baseline and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)

  19. SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CRQ-SAS Dyspnea Domain (DD) Response Rated as "Better"

    The threshold of response (TOR) is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit. The TOR was evaluated as the change from Baseline in the SOBDA score based on CRQ-SAS scores pre-specified as "better" or demonstrating meaningful improvement. The CRQ-SAS DD includes 5 questions (q.) scored 1 (maximum impairment) to 7 (no impairment). Individual q. were equally weighted, and domain scores (DSs) (range=1-7) were calculated as the mean across the non-missing items within each domain (DSs were calculated although an individual item score was missing).

    Time frame: Baseline and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)

  20. SOBDA Threshold for Response Assessed as Mean Change From Baseline to Last Treatment Week in the SOBDA Score Based on Forced Expiratory Volume in One Second (FEV1) Change From Baseline of 50 Milliliters (mL) to <100 mL

    FEV1 response was rated as 1=No change or worse (i.e., change of \<50 mL); 2=Better (i.e., change of 50 to \<100 mL); 3=Much better (i.e., change of \>=100 mL). The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on study assessment (FEV1) scores pre-specified as "better" or demonstrating meaningful improvement.

    Time frame: Baseline and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)

07

Results

Posted Mar 15, 2012

Participant flow

The number of participants "enrolled" in the Protocol reflects the number of participants starting treatment in the Double-blind Treatment Period.

2-week Run-in Period
Participant flow — 2-week Run-in Period
MilestoneAlbuterol and/or Ipratropium: Run-in PeriodPlacebo: Double-blind Treatment PeriodSAL 50 mcg: Double-blind Treatment PeriodFSC 250/50 mcg: Double-blind Treatment Period
Started418000
Completed366000
Not completed52000
Withdrew: Adverse event8000
Withdrew: Protocol violation5000
Withdrew: Study closed/terminated2000
Withdrew: Lost to follow-up3000
Withdrew: Physician decision10000
Withdrew: Withdrawal by subject10000
Withdrew: Did not meet continuation criteria14000
6-week Double-blind Treatment Period
Participant flow — 6-week Double-blind Treatment Period
MilestoneAlbuterol and/or Ipratropium: Run-in PeriodPlacebo: Double-blind Treatment PeriodSAL 50 mcg: Double-blind Treatment PeriodFSC 250/50 mcg: Double-blind Treatment Period
Started075152139
Completed069141126
Not completed061113
Withdrew: Adverse event0337
Withdrew: Lack of efficacy0201
Withdrew: Protocol violation0004
Withdrew: Study closed/terminated0010
Withdrew: Withdrawal by subject0171

Outcome measures

PrimaryInternal Consistency (IC) of the Shortness of Breath With Daily Activities (SOBDA) Questionnaire in Participants With Chronic Obstructive Pulmonary Disease (COPD) Assessed as Cronbach's Alpha Value

Cronbach's alpha (CA) is a measure of the IC of the 13-item SOBDA questionnaire (completed via electronic diary by a sample of participants). It is the ratio of the variance (var.) of the sum of the individual scores and the var. of the total score. The var. of the sum of a group of independent variables is the sum of their var.; thus, if the variables are positively correlated, the var. of the sum will be increased. If the items making up the score are identical and so perfectly correlated, CA=1. If the items are independent, CA=0. Higher scores indicate a more reliable (precise) instrument.

Time frame:
Day 1 of the 2-week Run-in Period
Reported as:
Number · ratio of variance
Internal Consistency (IC) of the Shortness of Breath With Daily Activities (SOBDA) Questionnaire in Participants With Chronic Obstructive Pulmonary Disease (COPD) Assessed as Cronbach's Alpha Value
ratio of varianceAll Participants: 2-week Run-in Period
Internal Consistency (IC) of the Shortness of Breath With Daily Activities (SOBDA) Questionnaire in Participants With Chronic Obstructive Pulmonary Disease (COPD) Assessed as Cronbach's Alpha Value0.892
PrimaryTest-retest Reliability (T-RR) of SOBDA Scores Measured as the Difference in the SOBDA Weekly Score Between Week 1 and Week 2 of the 2-week Run-in Period

T-RR=stability during repeat measures over time in a stable population. SOBDA score was determined by the 13-item (it.) scoring algorithm, assigning a weekly mean score of 1-4 (higher scores=more severe breathlessness with daily activities) based on the mean of 7 days of data (or \>=4 days). Daily total score is computed from the mean of the participant's (par.) scores on the 13 it. (\>=7 it. must have non-missing responses). Only scores of stable par. (indicating no change \[score=3\] on the par.-completed Patient Global Assessment of Change \[PGAC\]; 1 \[ much worse\] to 5 \[much better\]) were used.

Time frame:
Week 1 and Week 2 of the 2-week Run-in Period
Reported as:
Mean · scores on a scale
Test-retest Reliability (T-RR) of SOBDA Scores Measured as the Difference in the SOBDA Weekly Score Between Week 1 and Week 2 of the 2-week Run-in Period
scores on a scaleAll Participants: 2-week Run-in Period
Test-retest Reliability (T-RR) of SOBDA Scores Measured as the Difference in the SOBDA Weekly Score Between Week 1 and Week 2 of the 2-week Run-in Period0.01 ± 0.244
Statistical analysis
  • All Participants: 2-week Run-in Period · t-test, 2 sided · p = 0.713 · Mean difference (final values): 0.01 · 95% CI -0.03 to 0.05
PrimaryConvergent Validity for the SOBDA Questionnaire Measured as Correlations of the Baseline SOBDA Score With Participant-completed Modified Medical Research Council (mMRC) and Physician-completed mMRC Scores at Visit 2

Convergent validity is defined as the ability of the SOBDA questionnaire to measure required information and was assessed by examining the relationship between the SOBDA score and the participant/physician-completed mMRC Dyspnea Scale assessments. The physician/participant rated the degree of the participant's dyspnea (trouble breathing) on the 5-point mMRC scale (0, none; 4, very severe). Spearman's rank correlation coefficient assesses if the relationship between two variables is monotone. A correlation of +1 or -1 will occur if one variable is a perfect monotone of the other.

Time frame:
Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)
Reported as:
Number · Spearman rank correlation coefficient
Convergent Validity for the SOBDA Questionnaire Measured as Correlations of the Baseline SOBDA Score With Participant-completed Modified Medical Research Council (mMRC) and Physician-completed mMRC Scores at Visit 2
Spearman rank correlation coefficientAll Participants: 2-week Run-in Period
Physician-completed mMRC, n=3390.24
Participant-completed mMRC, n=3400.29
PrimaryConvergent Validity for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Clinician Global Assessment of Dyspnea Severity (CGI-S) Score at Visit 2

Convergent validity is defined as the ability of the SOBDA questionnaire to measure the required information and was assessed by examining the relationship between the SOBDA score with the CGI-S score. Spearman's rank correlation coefficient assesses if the relationship between two variables is monotone. A correlation of +1 or -1 will occur if one variable is a perfect monotone of the other. Clinicians were asked to assess the severity of the participant's dyspnea on the CGI-S scale. This was evaluated on a 1-4 Likert scale: 1 (mild) to 4 (very severe).

Time frame:
Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)
Reported as:
Number · Spearman rank correlation coefficient
Convergent Validity for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Clinician Global Assessment of Dyspnea Severity (CGI-S) Score at Visit 2
Spearman rank correlation coefficientAll Participants: 2-week Run-in Period
Convergent Validity for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Clinician Global Assessment of Dyspnea Severity (CGI-S) Score at Visit 20.24
PrimaryConvergent Validity (CV) for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) Dyspnea Domain Score at Visit 2

Convergent validity is defined as the ability of the SOBDA questionnaire to measure required information and was assessed by examining the relationship between the SOBDA score and the CRQ-SAS dyspnea domain score. Pearson's correlation coefficient is a measure of the linear dependence between 2 variables. A correlation of +1 or -1 will occur if the data from the 2 variables lie exactly on a line. The CRQ is a 20-item instrument measuring 4 domains (each measured on a scale of 1 \[maximum impairment\] to 7 \[no impairment\]) of functioning: mastery, fatigue, emotional function, and dyspnea.

Time frame:
Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)
Reported as:
Number · Pearson's correlation coefficient
Convergent Validity (CV) for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) Dyspnea Domain Score at Visit 2
Pearson's correlation coefficientAll Participants: 2-week Run-in Period
Convergent Validity (CV) for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) Dyspnea Domain Score at Visit 2-0.68
PrimaryKnown Group Validity for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of the Physician-completed (PyC) mMRC Score at Visit 2

SOBDA known group validity refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the PyC mMRC. The physician rated the degree of the participant's dyspnea on the 5-point mMRC scale: 0 (none) to 4 (very severe). Known group validity was confirmed if the SOBDA score increased with increasing values of PyC mMRC, both indicating increased levels of breathlessness.

Time frame:
Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)
Reported as:
Least squares mean · scores on a scale
Known Group Validity for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of the Physician-completed (PyC) mMRC Score at Visit 2
scores on a scaleAll Participants: 2-week Run-in Period
PyC mMRC: 0 to 1, n=121.78 ± 0.196
PyC mMRC: 2, n=2002.08 ± 0.048
PyC mMRC: 3, n=1172.28 ± 0.063
PyC mMRC: 4, n=102.73 ± 0.216
Statistical analysis
  • All Participants: 2-week Run-in Period · ANCOVA · p = <0.001 (Analysis of covariance (ANCOVA) adjusted for age, gender, and percent predicted Forced Expiratory volume in one second (FEV1) at Screening.)
PrimaryKnown Group Validity for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of the Participant-completed (ParC) mMRC Score at Visit 2

SOBDA known group validity refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the ParC mMRC. The participant rated the degree of his/her dyspnea on the 5-point mMRC scale: 0 (none) to 4 (very severe). Known group validity was confirmed if the SOBDA score increased with increasing values of ParC mMRC, both indicating increased levels of breathlessness.

Time frame:
Baseline (last week of the 2-week Run-in Period) and pre-treatment on Visit 2 (Day 1 of the 6-week Treatment Period)
Reported as:
Least squares mean · scores on a scale
Known Group Validity for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of the Participant-completed (ParC) mMRC Score at Visit 2
scores on a scaleAll Participants: 2-week Run-in Period
ParC mMRC: 0, n=121.92 ± 0.192
ParC mMRC: 1, n=1031.94 ± 0.066
ParC mMRC: 2, n=1382.20 ± 0.056
ParC mMRC: 3, n=652.26 ± 0.083
ParC mMRC: 4, n=222.73 ± 0.142
Statistical analysis
  • All Participants: 2-week Run-in Period · ANCOVA · p = <0.001 (ANCOVA adjusted for age, gender, and percent predicted FEV1 at Screening.)
PrimaryKnown Group Validity (KGV) for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of CGI-S Scores at Visit 2

SOBDA KGV refers to the extent to which scores from the SOBDA questionnaire should differentiate participants with varying levels of dyspnea severity. It was assessed by comparing summary measures for the SOBDA score for each indicated level (0, 1, 2, 3, and 4) of the CGI-S score. Clinicians were asked to assess the severity of the participant's dyspnea on the CGI-S scale. This was evaluated on a 1-4 Likert scale: 1 (mild) to 4 (very severe). KGV was confirmed if the SOBDA score increased with increasing values of CGI-S, both indicating increased levels of breathlessness.

Time frame:
Baseline (last week of the 2-week Run-in Period) and pre-treatement on Visit 2 (Day 1 of the 6-week Treatment Period)
Reported as:
Least squares mean · scores on a scale
Known Group Validity (KGV) for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of CGI-S Scores at Visit 2
scores on a scaleAll Participants: 2-week Run-in Period
CGI-S: 1, n=191.87 ± 0.156
CGI-S: 2, n=2362.11 ± 0.045
CGI-S: 3, n=782.33 ± 0.080
CGI-S: 4, n=52.72 ± 0.305
Statistical analysis
  • All Participants: 2-week Run-in Period · ANCOVA · p = 0.008 (ANCOVA adjusted for age, gender, and percent predicted FEV1 at Screening)
PrimaryParticipants (Par.) Classified as Responders/Non-responders According to the Patient Global Assessment of Change (PGAC) Response at Days 8, 15, 22, 29, 36, and 43 and at Visit 3/Premature Discontinuation (PD) (the End of the 6-week Treatment Period or PD)

The PGAC is par. completed on a 1-5 scale: 1, much worse; 2, worse; 3, no change; 4, better; 5, much better. Responders were defined as par. with a rating of "better" or "much better" (score of 4 or 5) on the PGAC at the relevant week; non-responders were defined as par. with a response of "much worse," "worse," or "no change" on the PGAC. As pre-specified in the study protocol, results are presented independent of treatment allocation . The study objectives were to assess the measurement properties and validity of the SOBDA questionnaire independent of specific treatment effect.

Time frame:
Days 8, 15, 22, 29, 36, and 43 and Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Reported as:
Number · participants
Participants (Par.) Classified as Responders/Non-responders According to the Patient Global Assessment of Change (PGAC) Response at Days 8, 15, 22, 29, 36, and 43 and at Visit 3/Premature Discontinuation (PD) (the End of the 6-week Treatment Period or PD)
participantsMITT Population: 6-Week Treatment Period
Responders, Day 8 (Baseline to Week 1), n=293105
Non-responders, Day 8 (Baseline to Week 1), n=293188
Responders, Day 15 (Week 1 to Week 2), n=30391
Non-responders, Day 15 (Week 1 to Week 2), n=303212
Responders, Day 22 (Week 2 to Week 3), n=29983
Non-responders, Day 22 (Week 2 to Week 3), n=299216
Responders, Day 29 (Week 3 to Week 4), n=28562
Non-responders, Day 29 (Week 3 to Week 4), n=285223
Responders, Day 36 (Week 4 to Week 5), n=27777
Non-responders, Day 36 (Week 4 to Week 5), n=277200
Responders, Day 43 (Week 5 to Week 6), n=11931
Non-responders, Day 43 (Week 5 to Week 6), n=11988
Responders, Last Treatment Week, n=15145
Non-responders, Visit 3/PD, n=151106
PrimaryChange From the Previous Week to the Current Week's SOBDA Score by Participant-completed PGAC Response at Days 8, 15, 22, 29, 36, and 43 and at Visit 3/PD (End of the 6-week Treatment Period or PD)

Responsiveness reflects the ability of the SOBDA questionnaire to detect change under conditions of known change. Responders (Rs)=participants (par.) with a rating of "better"/"much better" (score of 4/5) on the PGAC (range; 1 \[much worse\] to 5 \[much better\]) at the relevant week; NRs=par. with a response of "much worse," "worse," or "no change" (score of 3). Mean difference between Rs and NRs in the change from the previous week to the current week's SOBDA score was calculated. For Visit 3/PD, the change from Baseline to the last treatment week's SOBDA score for Rs and NRs was calculated.

Time frame:
Baseline; Days 8, 15, 22, 29, 36, and 43 and Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Reported as:
Mean · scores on a scale
Change From the Previous Week to the Current Week's SOBDA Score by Participant-completed PGAC Response at Days 8, 15, 22, 29, 36, and 43 and at Visit 3/PD (End of the 6-week Treatment Period or PD)
scores on a scaleMITT Population: 6-Week Treatment Period
Baseline to Day 8, responders, n=105-0.26 ± 0.324
Baseline to Day 8, non-responders, n=188-0.01 ± 0.254
Day 8 to Day 15, responders, n=91-0.10 ± 0.280
Day 8 to Day 15, non-responders, n=2120.01 ± 0.222
Day 15 to Day 22, responders, n=83-0.08 ± 0.223
Day 15 to Day 22, non-responders, n=2160.02 ± 0.183
Day 22 to Day 29, responders, n=62-0.09 ± 0.198
Day 22 to Day 29, non-responders, n=2230.01 ± 0.193
Day 29 to Day 36, responders, n=77-0.07 ± 0.245
Day 29 to Day 36, non-responders, n=2000.03 ± 0.169
Day 36 to Day 43, responders, n=31-0.04 ± 0.167
Day 36 to Day 43, non-responders, n=880.02 ± 0.240
Baseline to Visit 3/PD, responders, n=45-0.21 ± 0.497
Baseline to Visit 3/PD, non-responders, n=106-0.14 ± 0.423
Statistical analysis
  • MITT Population: 6-Week Treatment Period · ANCOVA · p = <0.001 (ANCOVA adjusted for age, gender, and SOBDA Baseline score; difference between responders and non-responders during Week prior to Day 8) · Mean difference (final values): 0.24 · 95% CI 0.18 to 0.31
  • MITT Population: 6-Week Treatment Period · ANCOVA · p = <0.001 (ANCOVA adjusted for age, gender, and SOBDA Baseline score; difference between responders and non-responders during Week prior to Day 15) · Median difference (final values): 0.12 · 95% CI 0.06 to 0.19
  • MITT Population: 6-Week Treatment Period · ANCOVA · p = <0.001 (ANCOVA adjusted for age, gender, and SOBDA Baseline score; difference between responders and non-responders during Week prior to Day 22) · Mean difference (final values): 0.11 · 95% CI 0.06 to 0.16
  • MITT Population: 6-Week Treatment Period · ANCOVA · p = <0.001 (ANCOVA adjusted for age, gender, and SOBDA Baseline score; difference between responders and non-responders during Week prior to Day 29) · Mean difference (final values): 0.11 · 95% CI 0.06 to 0.17
  • MITT Population: 6-Week Treatment Period · ANCOVA · p = <0.001 (ANCOVA adjusted for age, gender, and SOBDA Baseline score; difference between responders and non-responders during Week prior to Day 36) · Mean difference (final values): 0.13 · 95% CI 0.08 to 0.18
  • MITT Population: 6-Week Treatment Period · ANCOVA · p = 0.180 (ANCOVA adjusted for age, gender, and SOBDA Baseline score; difference between responders and non-responders during Week prior to Day 43) · Mean difference (final values): 0.06 · 95% CI -0.03 to 0.15
  • MITT Population: 6-Week Treatment Period · ANCOVA · p = 0.307 (ANCOVA adjusted for age, gender, and SOBDA Baseline score; difference between responders and non-responders during Week prior to Visit 3/PD) · Mean difference (final values): 0.08 · 95% CI -0.07 to 0.23
PrimaryNumber of Participants Classified as Responders and Non-responders by Clinician Global Impression of Change Question (CGI-C) Response at Visit 3/PD

Clinicians were asked to provide their clinical impression regarding change in the participant's shortness of breath by CGI-C. This was evaluated on a 1-5 Likert scale: 1 (much worse) to 5 (much better), with 3 being no change. A CGI-C responder was defined as a participant who had a response of "better" (4) or "much better" (5), and a non-responder was defined as a participant who had a response of "much worse" (1), "worse" (2), or "no change" (3).

Time frame:
Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Reported as:
Number · participants
Number of Participants Classified as Responders and Non-responders by Clinician Global Impression of Change Question (CGI-C) Response at Visit 3/PD
participantsMITT Population: 6-Week Treatment Period
Responders120
Non-responders181
PrimaryNumber of Participants Classified as Responders and Non-responders by CRQ-SAS Dyspnea Domain Response at Visit 3/PD

A CRQ-SAS dyspnea domain responder was defined as a participant who had a score increase of 0.5 units or more for the dyspnea domain of the CRQ-SAS between Visit 2 and Visit 3/Premature Discontinuation. A non-responder was defined as a participant who had a decrease in the score, or an increase of less than 0.5 units.

Time frame:
Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Reported as:
Number · participants
Number of Participants Classified as Responders and Non-responders by CRQ-SAS Dyspnea Domain Response at Visit 3/PD
participantsMITT Population: 6-Week Treatment Period
Responders117
Non-responders184
PrimaryNumber of Participants Classified as Responders and Non-responders by Physician-completed and Participant-completed mMRC Response at Visit 3/PD

A Physician-completed and Participant-completed mMRC responder was defined as a participant who had a score decrease of one unit or more between Visit 2 and Visit 3/Premature Discontinuation. A non-responder was defined as a participant who had the same score or an increase in score.

Time frame:
Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Reported as:
Number · participants
Number of Participants Classified as Responders and Non-responders by Physician-completed and Participant-completed mMRC Response at Visit 3/PD
participantsMITT Population: 6-Week Treatment Period
Physician-completed mMRC responders91
Physician-completed mMRC non-responders210
Participant-completed mMRC responders92
Participant-completed mMRC non-responders209
PrimaryChange From Baseline to Last Treatment Week in the SOBDA Score by CGI-C Responses at Visit 3/PD

The responsiveness of the SOBDA questionnaire was assessed by comparing score changes between responders and non-responders. The CGI-C is clinician completed on a 1 to 5 scale: 1, much worse; 2, worse; 3, no change; 4, better; 5, much better. Changes in mean SOBDA scores during the last week of treatment in responders and non-responders using definitions based on the CGI-C conducted at Visit 3/Premature Discontinuation were assessed.

Time frame:
Baseline (2-week Run-in Period) and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Reported as:
Mean · scores on a scale
Change From Baseline to Last Treatment Week in the SOBDA Score by CGI-C Responses at Visit 3/PD
scores on a scaleMITT Population: 6-Week Treatment Period
Responders, n=120-0.25 ± 0.484
Non-responders, n=181-0.03 ± 0.413
Statistical analysis
  • MITT Population: 6-Week Treatment Period · ANCOVA · p = <0.001 (ANCOVA adjusted for age, gender, and SOBDA Baseline score; comparision of mean SOBDA score for CGI-C responders and non-responders) · Mean difference (final values): 0.24 · 95% CI 0.14 to 0.34
PrimaryChange From Baseline to Last Treatment Week in the SOBDA Score by CRQ-SAS Dyspnea Domain (DD) Responses at Visit 3/PD

The responsiveness of the SOBDA questionnaire was assessed by comparing score changes of responders (Rs) versus non-responders (NRs). The CRQ-SAS DD includes 5 questions (q.) scored 1 (maximum impairment) to 7 (no impairment). Individual q. were equally weighted, and domain scores (DSs) (range=1-7) were calculated as the mean across the non-missing items within each domain (DSs were calculated although an individual item score was missing). Changes in mean SOBDA scores during the last treatment week in Rs and NRs using definitions based on the CRQ-SAS DD conducted at Visit 3/PD were assessed.

Time frame:
Baseline (2-week Run-in Period) and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Reported as:
Mean · Scores on a scale
Change From Baseline to Last Treatment Week in the SOBDA Score by CRQ-SAS Dyspnea Domain (DD) Responses at Visit 3/PD
Scores on a scaleMITT Population: 6-Week Treatment Period
Responders, n=117-0.32 ± 0.446
Non-responders, n=1840.01 ± 0.416
Statistical analysis
  • MITT Population: 6-Week Treatment Period · ANCOVA · p = <0.001 (ANCOVA adjusted for age, gender, and SOBDA Baseline score; comparision of mean SOBDA score for CRQ-SAS Dyspnea Domain responders and non-responders) · Median difference (final values): 0.30 · 95% CI 0.21 to 0.40
PrimaryChange From Baseline to Last Treatment Week in the SOBDA Score by Physician-completed mMRC and Participant-completed mMRC Responses at Visit 3/PD

The responsiveness of the SOBDA questionnaire was assessed by comparing score changes between responders and non-responders. The mMRC ranges from 0 (no breathlessness except with strenous exercise) to 4 (too breathless to leave the house; breathless when dressing/undressing) and is completed by the clinician or the participant as indicated. Changes in mean SOBDA scores during the last week of treatment in responders and non-responders using definitions based on the Physician-completed (Ph-C) and Participant-completed (Pa-C) mMRC conducted at Visit 3/Premature Discontinuation were assessed.

Time frame:
Baseline (2-week Run-in Period) and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Reported as:
Mean · Scores on a scale
Change From Baseline to Last Treatment Week in the SOBDA Score by Physician-completed mMRC and Participant-completed mMRC Responses at Visit 3/PD
Scores on a scaleMITT Population: 6-Week Treatment Period
Ph-C mMRC, responders, n=91-0.13 ± 0.416
Ph-C mMRC, non-responders, n=210-0.11 ± 0.472
Pa-C mMRC, responders, n=92-0.18 ± 0.508
Pa-C mMRC, non-responders, n=209-0.09 ± 0.428
Statistical analysis
  • MITT Population: 6-Week Treatment Period · ANCOVA · p = 0.535 (ANCOVA adjusted for age, gender, and SOBDA Baseline score; comparision of mean SOBDA score for Physician-Completed mMRC responders and non-responders) · Median difference (final values): 0.03 · 95% CI -0.08 to 0.15
  • MITT Population: 6-Week Treatment Period · ANCOVA · p = 0.08 (ANCOVA adjusted for age, gender, and SOBDA Baseline score; comparison of mean SOBDA score for Participant-Completed mMRC responders and non-responders) · Median difference (final values): 0.08 · 95% CI -0.02 to 0.19
PrimarySOBDA Threshold for Response Assessed as Mean Change From the Previous Week's SOBDA Score Based on a Participant-completed PGAC Score Rated of "Better"

Changes from Baseline in the SOBDA score for responders (Rs) and non-responders (NRs) (using the PGAC assessment; 1 \[much worse\] to 5 \[much better\]), together with the cumulative proportions of Rs and NRs, was used to establish the threshold for defining SOBDA questionnaire Rs. The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on PGAC scores pre-specified as "better" or demonstrating meaningful improvement.

Time frame:
Baseline (last week of the 2-week Run-in Period) and Weeks 1, 2, 3, 4, 5, and 6 (6-week Treatment Period)
Reported as:
Mean · scores on a scale
SOBDA Threshold for Response Assessed as Mean Change From the Previous Week's SOBDA Score Based on a Participant-completed PGAC Score Rated of "Better"
scores on a scaleMITT Population: 6-Week Treatment Period
Baseline to Week 1, n=97-0.26 ± 0.325
Week 1 to Week 2, n=82-0.08 ± 0.219
Week 2 to Week 3, n=70-0.08 ± 0.216
Week 3 to Week 4, n=49-0.10 ± 0.216
Week 4 to Week 5, n=66-0.08 ± 0.255
Week 5 to Week 6, n=26-0.05 ± 0.181
PrimarySOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CGI-C Response Rated as "Better"

The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on CGI-C scores pre-specified as "better" or demonstrating meaningful improvement. The CGI-C is clinician completed on a 1 to 5 scale: 1, much worse, 2, worse; 3, no change; 4, better; 5, much better.

Time frame:
Baseline and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Reported as:
Mean · Scores on a scale
SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CGI-C Response Rated as "Better"
Scores on a scaleMITT Population: 6-Week Treatment Period
SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CGI-C Response Rated as "Better"-0.25 ± 0.484
PrimarySOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CRQ-SAS Dyspnea Domain (DD) Response Rated as "Better"

The threshold of response (TOR) is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit. The TOR was evaluated as the change from Baseline in the SOBDA score based on CRQ-SAS scores pre-specified as "better" or demonstrating meaningful improvement. The CRQ-SAS DD includes 5 questions (q.) scored 1 (maximum impairment) to 7 (no impairment). Individual q. were equally weighted, and domain scores (DSs) (range=1-7) were calculated as the mean across the non-missing items within each domain (DSs were calculated although an individual item score was missing).

Time frame:
Baseline and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Reported as:
Mean · Scores on a scale
SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CRQ-SAS Dyspnea Domain (DD) Response Rated as "Better"
Scores on a scaleMITT Population: 6-Week Treatment Period
SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CRQ-SAS Dyspnea Domain (DD) Response Rated as "Better"-0.13 ± 0.417
PrimarySOBDA Threshold for Response Assessed as Mean Change From Baseline to Last Treatment Week in the SOBDA Score Based on Forced Expiratory Volume in One Second (FEV1) Change From Baseline of 50 Milliliters (mL) to <100 mL

FEV1 response was rated as 1=No change or worse (i.e., change of \<50 mL); 2=Better (i.e., change of 50 to \<100 mL); 3=Much better (i.e., change of \>=100 mL). The threshold of response is a score change in the SOBDA questionnaire that is demonstrated to have a perceivable benefit for the participant. The threshold of response was evaluated as the change from Baseline in the SOBDA score based on study assessment (FEV1) scores pre-specified as "better" or demonstrating meaningful improvement.

Time frame:
Baseline and Week Prior to Visit 3/PD (end of 6-week Treatment Period or earlier up to Week 8)
Reported as:
Mean · mL
SOBDA Threshold for Response Assessed as Mean Change From Baseline to Last Treatment Week in the SOBDA Score Based on Forced Expiratory Volume in One Second (FEV1) Change From Baseline of 50 Milliliters (mL) to <100 mL
mLMITT Population: 6-Week Treatment Period
SOBDA Threshold for Response Assessed as Mean Change From Baseline to Last Treatment Week in the SOBDA Score Based on Forced Expiratory Volume in One Second (FEV1) Change From Baseline of 50 Milliliters (mL) to <100 mL-0.16 ± 0.492

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—4/75 (5.3%)14/75 (18.7%)
SAL 50 mcg—5/151 (3.3%)34/151 (22.5%)
FSC 250/50 mcg—3/139 (2.2%)37/139 (26.6%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPlaceboSAL 50 mcgFSC 250/50 mcg
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders4/752/1510/139
Respiratory FailureRespiratory, thoracic and mediastinal disorders0/750/1511/139
Myocardial InfarctionCardiac disorders0/750/1511/139
Suicide AttemptPsychiatric disorders0/750/1511/139
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders0/751/1510/139
PneumothoraxRespiratory, thoracic and mediastinal disorders0/751/1510/139
Impaired Gastric EmptyingGastrointestinal disorders0/751/1510/139
Chest PainGeneral disorders0/751/1510/139
PneumoniaInfections and infestations0/751/1510/139
DehydrationMetabolism and nutrition disorders0/751/1510/139
Most frequent other events
Showing 10 of 93
Most frequent other events
EventPlaceboSAL 50 mcgFSC 250/50 mcg
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders4/753/1510/139
HeadacheNervous system disorders2/756/1515/139
DyspneaRespiratory, thoracic and mediastinal disorders2/754/1511/139
Respiratory Tract InfectionInfections and infestations2/750/1510/139
CandidiasisInfections and infestations1/750/1513/139
Sinus HeadacheNervous system disorders0/750/1513/139
CoughRespiratory, thoracic and mediastinal disorders0/753/1512/139
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders0/753/1510/139
Chest PainGeneral disorders1/753/1510/139
Sinus CongestionRespiratory, thoracic and mediastinal disorders0/751/1512/139

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboSAL 50 mcgFSC 250/50 mcgAlbuterol and/or Ipratropium: Run-in FailureTotal
Mean62.8 ± 9.8260.1 ± 9.5860.2 ± 9.4563.8 ± 9.6161.1 ± 9.65
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSAL 50 mcgFSC 250/50 mcgAlbuterol and/or Ipratropium: Run-in FailureTotal
Female29636027179
Male46897925239
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboSAL 50 mcgFSC 250/50 mcgAlbuterol and/or Ipratropium: Run-in FailureTotal
African American/African Heritage91212841
Asian10001
White6514012744376
08

Study locations

39 sites
  • GSK Investigational Site
    Jasper, Alabama 35501, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Los Angeles, California 90095-1690, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Wheat Ridge, Colorado 80033, United States
  • GSK Investigational Site
    Stamford, Connecticut 06902, United States
  • GSK Investigational Site
    Tamarac, Florida 33321, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30046, United States
  • GSK Investigational Site
    Evansville, Indiana 47710, United States
  • GSK Investigational Site
    Evansville, Indiana 47714, United States
  • GSK Investigational Site
    South Bend, Indiana 46617, United States
  • GSK Investigational Site
    Madisonville, Kentucky 42431, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70115, United States
  • GSK Investigational Site
    Sunset, Louisiana 70584, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63141, United States
  • GSK Investigational Site
    Summit, New Jersey 07091, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Elizabeth City, North Carolina 27909, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Lake Oswego, Oregon 97035, United States
  • GSK Investigational Site
    Portland, Oregon 97213, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406-7108, United States
  • GSK Investigational Site
    Chester, South Carolina 29706, United States
  • GSK Investigational Site
    Clinton, South Carolina 29325, United States
  • GSK Investigational Site
    Easley, South Carolina 29640, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Greenwood, South Carolina 29646, United States
  • GSK Investigational Site
    Seneca, South Carolina 29678, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Johnson City, Tennessee 37601, United States
  • GSK Investigational Site
    Houston, Texas 77054, United States
  • GSK Investigational Site
    New Braunfels, Texas 78130, United States
  • GSK Investigational Site
    Abingdon, Virginia 24210, United States
  • GSK Investigational Site
    Richmond, Virginia 23229, United States
  • GSK Investigational Site
    Spokane, Washington 99204, United States
09

References and documents

Publications

  • Watkins ML, Wilcox TK, Tabberer M, Brooks JM, Donohue JF, Anzueto A, Chen WH, Crim C. Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease. BMJ Open. 2013 Oct 22;3(10):e003048. doi: 10.1136/bmjopen-2013-003048. PubMed 24154513 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 1 year 8 months after primary completion. A results delay was requested in Feb 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2009
First posted
Sep 25, 2009
Start
Oct 29, 2009
Primary completionActual
Jul 1, 2010
CompletionActual
Jul 1, 2010
Results delay requested
Feb 24, 2011
Results first posted
Mar 15, 2012
Last update
Aug 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00984659
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 25, 2009
Start date
Oct 29, 2009
Primary completion
Jul 1, 2010
Completion
Jul 1, 2010
Results posted
Mar 15, 2012
Last update
Aug 29, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Salmeterol Xinafoate

Start the discussion